CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The MERIT project is focused on developing personalized RNA-based immunotherapies for triple-negative breast cancer. It aims to create individualized vaccines targeting specific tumor mutations to improve treatment outcomes.
The Mutanome Engineered RNA Immuno-Therapy (MERIT) project aims to clinically translate and industrially validate a pioneering RNA-based immunotherapy approach to target the individual tumour antigen signature. MERIT focuses on previous inventions, fits into the overall business and innovation needs of the partners, and addresses triple-negative breast cancer patients with high medical need.
The MERIT concept, including patents and potential products, was developed using EU FP6 funding.
The inno…
BIONTECH AG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, Villejuif
Type: Research institute
Activity type: Research Organisations
SME: No
Belgium, Bruxelles / Brussel
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Switzerland, ZURICH
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Sweden, Uppsala
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
